# Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

> **NCT01731652** · PHASE2 · COMPLETED · sponsor: **Telormedix SA** · enrollment: 12 (actual)

## Conditions studied

- Carcinoma in Situ
- Non Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** TMX-101

## Key facts

- **NCT ID:** NCT01731652
- **Lead sponsor:** Telormedix SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01731652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01731652, "Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01731652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*